BioAge Stock Rallies 29% Following Upsized $198M IPO
RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $362
Dow, S&P 500 Retreat From Record Highs
Amgen Stock Slides 5% as Analysts Weigh in on Drug Study Results
Amgen Stock Slips 3% Following Phase 3 Data for Rocatinlimab, Uplizna
Analyst Expectations For Amgen's Future
Equities Mostly Fall Intraday as Traders Weigh Macro Data
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
BioAge, Obesity Drug Developer, Upsizes Proposed IPO
Amgen Falls on Disappointing Drug Data -- WSJ
Shareholders Should Be Pleased With Amgen Inc.'s (NASDAQ:AMGN) Price
Express News | Amgen Shares Down 4.6% After Co Reports Mixed Data on Two Drugs
Amgen Analyst Ratings
Express News | Amgen Shares Are Trading Lower After Following Atopic Dermatitis Data, Which Some Analysts Noted Did Not Meet Expectations Amid Competition in the Market
Baird Maintains Amgen(AMGN.US) With Sell Rating, Maintains Target Price $215
Leerink Partners Maintains Amgen(AMGN.US) With Hold Rating
Amgen, Visa Share Losses Lead Dow's 100-Point Drop
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
A Quick Look at Today's Ratings for Amgen(AMGN.US), With a Forecast Between $344 to $381
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market